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Background: Pin1 promotes oncogenesis by regulating multiple oncogenic signaling. In this study, we investigated
the involvement of Pin1 in tumor progression and in the prognosis of human esophageal squamous cell carcinoma
(ESCC).
Results: We observed that proliferation, clonogenicity and tumorigenesis of CE81T cells were inhibited by Pin1
knockdown. We next analyzed Pin1 expression in clinical ESCC specimens. When compared to the corresponding
non-tumor part, Pin1 protein and mRNA levels in tumor part were higher in 84% and 62% patients, respectively.
By immunohistochemistry, we identified that high Pin1 expression was associated with higher primary tumor stage
(p = 0.035), higher overall cancer stage (p = 0.047) and poor overall survival (p < 0.001). Furthermore, the association
between expression of Pin1 and levels of β-catenin and cyclin D in cell line and clinical specimens was evaluated.
β-catenin and cyclin D1 were decreased in CE81T cells with Pin1 knockdown. Cyclin D1 level correlated with Pin1
expression in clinical ESCC specimens.
Conclusions: Pin1 upregulation was associated with advanced stage and poor prognosis of ESCC. Pin1 knockdown
inhibited aggressiveness of ESCC cells. β-catenin and cyclin D1 were positively regulated by Pin1. These results
indicated that targeting Pin1 pathway could represent a potential modality for treating ESCC.
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Esophageal cancer is the eighth most common incident
cancer and the sixth leading cause of cancer death in
the world [1]. Squamous cell carcinoma is one of the
major histological type of esophageal cancer [2,3]. Despite
combined-modality treatment, most patients with esopha-
geal squamous cell carcinoma (ESCC) eventually have a
relapse and die from the disease [4]. It is imperative to in-
vestigate biomarkers and to find novel treatment targets
in ESCC.
Protein interacting with NIMA (never in mitosis A)-1
(Pin1) is overexpressed in several human cancers and
correlated with poor outcome of patients [5,6]. It is an* Correspondence: pjlu2190@mail.ncku.edu.tw
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can result in a substantial conformational change of the
target proteins leading to alterations in their function,
stability and/or intracellular localization. It promotes
oncogenesis by regulating multiple oncogenic signaling
at various levels [6-8].
Pin1 overexpression was previously reported to be cor-
related with lymph node metastasis and poor overall sur-
vival in ESCC patients treated with surgery [9,10]. In
patients treated with definitive chemoradiotherapy, the
clinical response in high Pin1 expression group was higher
than that of the low expression group [11]. However, the
role of Pin1 has not been experimentally examined in
ESCC cell lines.
This study evaluated the effects of Pin1 knockdown on
proliferation and tumorigenesis of ESCC cells. We also
determined the relationship between Pin1 expression. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ESCC patients. In addition, we examined the association
of Pin1 expression and levels of β-catenin and cyclin D1
in ESCC cell line and clinical specimens.
Methods
Patients’ clinicopathological data and sample preparation
We enrolled 89 ESCC patients who underwent esophagec-
tomy and regional lymph node dissection in the Kaohsiung
Veterans General Hospital from 1989 to 2004. No patient
received neo-adjuvant treatment. Clinicopathological infor-
mation was collected and samples of representative cancer-
ous and adjacent noncancerous tissues were obtained
with informed consent. The study was conducted under
approval of the Institutional Review Board of Kaohsiung
Veterans General Hospital of Taiwan.
Cell culture
Human ESCC cell line CE81T was obtained from the
Bioresource Collection and Research Center in Taiwan.
Cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) containing supplements.
Pin1-shRNA preparation and transfection
CE81T cells were cultured into the 6-well plates with
antibiotic-free DMEM. On the next day, cells were
transfected with 4 μg Pin1-shRNA in 4 ml Opti-MEM
and 21 μl Arrest-In Transfection Reagent (Expression
ArrestTM) for 12 hours. To select cells with stable Pin1
knockdown, we cultured cells in medium containing
4 μg/ml puromycin for 3 weeks. Pin1 knockdown was
confirmed by western blot and RT-PCR.
Gene transfection
For CE81T parental and the clone 48 cell transfection, we
used MicroPorator, a pipette-type electroporation system
(NanoEnTek Inc., Seoul, Korea). Indicated reporter and
expressing plasmids were introduced into dissociated cells
according to the manufacturer’s instructions (2 pulses
with 20 ms duration at 1400 V; Digital Bio Technology).
After 24 hours of recovery, the cells were subjected to
experiments.
Western blot
Cells or tissues lysates were prepared and subjected to
gel electrophoresis. Western blot analysis was performed
using anti-β-catenin (sc-7963, Santa Cruz), anti-cyclin
D1 (sc-718, Santa Cruz; ab16663, Abcam), anti-β-actin
(A5441, Sigma), anti-HA (ab18181, Abcam) and anti-
Pin1 (sc-15304, Santa Cruz).
RNA extraction and reverse transcription-PCR (RT-PCR)
Total RNA from cell lines or tissues was extracted by
Trizol solution (Invitrogen). Complementary DNA (cDNA)was synthesized from total RNA with ImProm-II™ reverse
transcriptase system kit (Promega Corporation). To detect
gene expressions, we used the synthesized cDNA for PCR








Cells were plated onto 96-well plates with 1 × 104 cells per
well. At indicated time, the medium was replaced by 120 μl
medium containing 0.33 mg/ml 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyl-2H-tetrazolium Bromide (MTT). After
2 hours, the reduced MTT was dissolved with DMSO.
Absorbance at 570 nm was determined.
Colony formation assay
For evaluating effect of Pin1 knockdown on clonogeni-
city, cells were plated into 6-well plates with 2 × 103 cells
per well. After 14 days, colonies (>50 cells per colony)
were fixed and stained with crystal violet in methanol. For
evaluating effect of cyclin D1 knockdown on clonogeni-
city, cells were plated into 6-well plates with 4 × 102 cells
per well. After 21 days, colonies (>50 cells per colony)
were fixed and stained. The colonies were counted using a
UMAX MagicScan (Techville, Inc., Dallas, TX, USA).
Xenograft tumor growth
For tumor xenografts, 5 × 106 cells in 100 μl HBSS were
injected s.c. into flank of nude mice obtained from National
Laboratory Animal Center of Taiwan and maintained in
accordance with institutional guidelines. Tumors were
measured weekly by caliper. Tumor volumes were calcu-
lated as: (width) × (length) × (height). The body weight and
survival time were also recorded.
Luciferase reporter assay
For evaluating β-catenin transactivation after Pin1 knock-
down or re-expression, TOPflash and FOPflash lucifer-
ase reporter plasmids were gifts of Dr Randall Moon
(Addgene plasmid #12456 and 12457, respectively). All
experimental groups were co-transfected with renilla lucif-
erase plasmids as internal control. The firefly luciferase
activity of TOPflash and FOPflash was normalized to
renilla luciferase activity. The ratio of TOPflash/FOPflash
(TOF/FOP-luc) was calculated. Cells were co-transfected
with indicated reporter and expressing plasmids. At
24 hours after transfection, luciferase activity was measured
by Luminoskan Ascent microplate luminometer (Thermo
Labsystems Inc., Franklin, MA, USA).
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We performed immunohistochemical studies to investigate
Pin1 expression in 89 ESCC paraffin-embedded slides.
Anti-Pin1 antibody (1:100 dilution; Oncogene Research)
was used. A positive reaction was indicated by reddish-
brown precipitates in the nucleus or cytoplasm. Expression
levels were classified based on the percentage of positive
cells and intensity of staining.Statistical analysis
SPSS software (version 17.0, SPSS, Inc., Chicago, IL) was
used. Correlations between Pin1 expression and clinico-
pathological variables were analyzed by chi-square test.
Survival rates were calculated by Kaplan–Meier method
and compared with log-rank test. In-vitro experiments
were done independently at least twice. The data were
compared by Student’s t-test. A p value less than 0.05










































Figure 1 Pin1 knockdown inhibited proliferation, clonogenicity and
Downregulation of Pin1 protein and mRNA was confirmed. (B) In MTT as
forming assay, the colony number was reduced after Pin1 knockdown. ** and
model, tumor size of cells with Pin1 knockdown was smaller than that of pareResults
Pin1 knockdown inhibited proliferation, clonogenicity and
tumorigenesis of ESCC
We knocked down Pin1 in CE81T cells. Downregulation
of Pin1 protein and mRNA was confirmed (Figure 1A).
MTT assay showed that proliferation of cells with Pin1
knockdown was attenuated (Figure 1B). The colony
number of cells with Pin1 knockdown was significantly
less than that of parental CE81T cells (p <0.01). The clo-
nogenicity of clone 48 cells with lower Pin1 level was
lower than clone 47 cells (Figure 1C). This result indi-
cated that Pin1 knockdown inhibited growth of ESCC
cells in a dose-dependent manner. Furthermore, we de-
veloped xenograft tumor with cells injected in subcutis
of nude mice. The tumor size from cells with Pin1
knockdown was smaller than that from parental CE81T
cells (Figure 1D). These results indicated that Pin1
knockdown inhibited proliferation, clonogenicity and











































tumorigenesis of ESCC. (A) Pin1 was knocked down in CE81T.
say, cell proliferation was attenuated after Pin1 knockdown. (C) In colony
*** denote to p <0.01 and p <0.001, respectively. (D) In xenograft tumor
ntal CE81T cells.
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specimens and correlated with poor prognosis of patients
Pin1 protein expression of 56 ESCC tumor and corre-
sponding non-tumor tissues was determined. We ob-
served that Pin1 in tumor part was higher in 47 (84%)A
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Figure 2 Pin1 upregulation was identified in ESCC specimens and
of 56 clinical ESCC tumor and corresponding non-tumor tissues was ex
according to the relative Pin1 expression in tumor part which was nor
(B) Pin1 mRNA level of 42 clinical ESCC tumor and corresponding non
the patient number according to the relative Pin1 mRNA in tumor part
expression of 89 ESCC tumors was examined by IHC. Expression was sc
intensity of staining (top panel). The bar chart showed the patient num
(D) Overall survival of patients was calculated by Kaplan-Meier method
expression has lower survival rate (p < 0.001). (E) The overall survival of
expression. Patients with high Pin1 expression had lower survival rate (patients when compared to corresponding non-tumor
part (Figure 2A). We further determined Pin1 mRNA
level of 42 tumor and corresponding non-tumor speci-
mens. Higher Pin1 mRNA level in tumor was identified






























































correlated with poor prognosis of patients. (A) Pin1 protein
amined (top panel). The bar chart showed the patient number
malized to the corresponding non-tumor part (bottom panel).
-tumor tissues was examined (top panel). The bar chart showed
which was normalized to non-tumor part (bottom panel). (C) Pin1
ored according to the percentage of positively stained cells and
ber according to Pin1 expression by IHC scoring (bottom panel).
and compared with log-rank test. Patients with high Pin1
55 patients with stage I and II disease were stratified by Pin1
p < 0.001).
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ESCC specimens.
We next utilized IHC to analyze Pin1 level in 89 ESCC
tumors. Pin1 expression was equivocal in 7 (8%) cases,
weakly positive in 32 (36%) cases, moderately positive in
36 (40%) cases and strongly positive in 14 (16%) cases
(Figure 2C). We categorized patients with moderately and
strongly positive Pin1 levels into the high Pin1 group. The
other patients were included in the low Pin1 group. Table 1
summarized the relationships between Pin1 expression
and clinicopathological parameters. High Pin1 expression
was associated with higher primary tumor stage (p =
0.035) and overall cancer stage (p = 0.047). The survival of
50 patients carrying high Pin1 level was significantly worse
than that of the 39 patients with low Pin1 expression (p <
0.001; Figure 2D). Furthermore, the overall survival of 55
patients with stage I and II disease were stratified by Pin1
expression. Patients with high Pin1 expression had lower
survival rate (p < 0.001; Figure 2E).
β-catenin and cyclin D1 were positively regulated by Pin1
β-catenin and cyclin D1 were known to be upregulated
by Pin1 [6-8]. In our study, we identified β-catenin andTable 1 The correlation between clinicopathologic
characteristics and Pin1 expression





Age (yrs) 33-81 37-81 33-80
(Median: 62) (Median: 63) (Median: 62)
≦62 46 20 26 1.000
>62 43 19 24
Sex
Male 84 36 48 0.650
Female 5 3 2
TNM classification
T
T1-2 41 23 18 0.035
T3-4 48 16 32
N
N0 39 20 19 0.282
N1 50 19 31
M
M0 87 39 48 0.502
M1 2 0 2
Stage 0.047
I-II 55 29 26
III-IV 34 10 24
Patients with moderately and strongly positive Pin1 levels were categorized
into the high Pin1 group. Patients with equivocal and weakly positive Pin1
levels were included in the low Pin1 group.cyclin D1 protein levels were decreased in clone 47 and
48 cells whose Pin1 was knocked down (Figure 3A). We
also observed that the transactivational potential of β-
catenin was reduced in clone 48 cells. Re-expression of
Pin1 in clone 48 cells significantly increased the β-catenin
transactivation (Figure 3B). To determine whether Pin1
regulated the aggressiveness of ESCC cells through cyclin
D1, we knocked down cyclin D1 in CE81T cells. The cell
proliferation was attenuated and clonogenicity was re-
duced in cells with cyclin D1 knockdown (Figure 3C and
D). These altered phenotypes were similar to those in-
duced by Pin1 knockdown. We next re-expressed cyclin
D1 in clone 48 cells. The inhibited tumorigenesis in clone
48 cells was partially recovered by cyclin D1 restoration
(Figure 3E).
Furthermore, we examined protein levels of β-catenin
and cyclin D1 in 56 ESCC tumor and corresponding non-
tumor tissues. When compared to the corresponding
non-tumor part, β-catenin and cyclin D1 expression in
tumor part were higher in 25 (45%) and 31 (55%) patients,
respectively (Figure 3F). Additionally, the high relative
Pin1 expression was associated with high cyclin D1 level
(p < 0.001). But the positive association between Pin1 and
β-catenin was not observed (p = 0.159) (Table 2). Collect-
ively, the results supported that β-catenin and cyclin D1
were positively regulated by Pin1 in ESCC.
Discussion
Pin1 can promote tumorigenesis by activating or stabil-
izing numerous oncoproteins and also inactivating or
destabilizing a number of tumor suppressors [8]. In this
study, we aimed to elucidate biological activities of Pin1
in ESCC cancer cells. The proliferation was attenuated
and clonogenicity was reduced in CE81T cells with Pin1
knockdown. Our result indicated that Pin1 knockdown
inhibited the growth of ESCC cells in a dose-dependent
manner. In xenograft tumor model, we observed that
the tumor size from cells with Pin1 knockdown was
smaller than that from parental CE81T cells. Collectively,
we provided evidence that Pin1 knockdown inhibited
proliferation and clonogenicity of ESCC in vitro and
tumorigenesis of ESCC in vivo.
The association between Pin1 expression and clinico-
pathlogical factors in ESCC was previously reported [9-11].
In this study, we examined Pin1 expression in ESCC speci-
mens. When compared to the corresponding non-tumor
part, Pin1 protein and mRNA levels in tumor part were
higher in 84% and 62% patients, respectively. We also in-
vestigated the Pin1 level in 89 primary ESCC tumor sam-
ples by IHC. Pin1 was expressed moderately or strongly in
56% ESCC tumors. The percentage of high Pin1 expression
in our patients was higher than that of earlier reports, in
which 31–37% of ESCC samples exhibited high Pin1 ex-
pression [9-11]. This difference might result from different
Figure 3 Pin1 positively regulated β-catenin and cyclin D1. (A) β-catenin and cyclin D1 were down-regulated by Pin1 knockdown in CE81T
cells. (B) Transactivational potential of β-catenin was reduced in clone 48 cells. Re-expression of Pin1 in clone 48 cells increased the transactivation
(top panel). Increased Pin1 and cyclin D1 levels after Pin1 re-expression in clone 48 cells were confirmed (bottom panel). (C) Cell proliferation
was attenuated by cyclin D1 knockdown in CE81T cells. (D) In colony forming assay, the colony number was reduced after cyclin D1 knockdown.
** denoted to p <0.01. (E) The inhibited tumorigenesis in clone 48 cells was partially recovered by restoration of cyclin D1 in xenograft tumor
model. Ectopic expression of cyclin D1 was confirmed by western blot (bottom panel). (F) Pin1, β-catenin and cyclin D1 in 56 clinical ESCC tumor
and corresponding non-tumor tissues were determined. Concomitant upregulation or downregulation of Pin1, β-catenin and cyclin D1 were
observed in more than 50% patients.
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studies indicated that Pin1 upregulation was common and
may be involved in ESCC carcinogenesis.
In this work, patients were primarily managed with
operations. Our result confirmed increased Pin1 expres-
sion was associated worse outcome of ESCC patients. Inaddition, Pin1 expression was significantly correlated
with primary tumor stage (p = 0.035) and overall cancer
stage (p = 0.047). These clinical observations correlated
with our experimental results that proliferation, clono-
genicity and tumorigenesis were positively affected by
Pin1 in ESCC.
Table 2 The correlation between Pin1 and expression of




High 23 2 0.159
Low 23 8
Cyclin D1
High 37 1 <0.001
Low 9 9
Patients with higher Pin1, β-catenin and cyclin D1 in tumor part when compared
to corresponding non-tumor part were categorized as high Pin1, β-catenin and
cyclin D1 groups, respectively.
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was controlled by Pin1-mediated cis/trans isomerization
[8]. Conceptually, β-catenin and cyclin D levels will be
positively correlated with Pin1 expression. In this study,
we showed the high relative Pin1 expression was signifi-
cantly associated with high cyclin D1 level (p < 0.001) in
clinical ESCC specimens. This finding was consistent with
the previous study [9]. On the other hand, concomitant
high or low Pin1 and β-catenin expressions were revealed
in our some patients. But we did not observe a significant
association between Pin1 and β-catenin expressions in
specimens. The possible explanation for this result that
only cyclin D1 but not β-catenin correlated with Pin1 in
our patients is the fact that Pin1 can increase cyclin D1
expression by multiple mechanisms. Therefore, it was
more probable to identify the positive association of Pin1
and cyclin D1 in specimens of limited number. Further-
more, we identified that β-catenin and cyclin D were
downregulated after Pin1 knockdown in CE81T cells. The
β-catenin transactivation was reduced in cells with Pin1
knockdown but increased after Pin1 re-expression. In
xenograft tumor models, the inhibited tumorigenesis in
cells with Pin1 knockdown was partially recovered by cyc-
lin D1 restoration. It is possible that Pin1 also regulates
ESCC tumorigenesis through other substrates such as c-
Jun, c-Myc and p53. The regulation of these molecules by
Pin1 in ESCC should be investigated in the future study.
Collectively, our data supported that β-catenin and cyclin
D1 were positively regulated by Pin1 in ESCC. Pin1 may
promote ESCC aggressiveness through β-catenin and cyc-
lin D.
Conclusion
In conclusion, Pin1 upregulation is common in ESCC.
The increased Pin1 expression may contribute to ad-
vanced cancer stage and inferior survival duration. The
experimental evidence that Pin1 knockdown inhibited
proliferation and clonogenicity of ESCC in vitro and
tumorigenesis of ESCC in vivo was provided. Targetingof the Pin1 pathway may constitute a potential treatment
modality for ESCC.
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